# How Scientists Create Human-Friendly Antibodies for Medicine

> This patent describes a method for modifying mouse antibodies so human immune systems accept them as their own, allowing them to be used as powerful, long-lasting medical treatments.

- **Patent:** US 5585089
- **Original title:** Humanized immunoglobulins
- **Owner:** Protein Design Labs Inc
- **Granted:** 1996
- **Status:** Public domain (expired)
- **Times cited:** 4,274
- **Field:** biotech, pharmaceutical

## What it does

The patent details a technique to 'humanize' antibodies originally derived from non-human sources, like mice. Because human bodies often reject mouse antibodies as foreign invaders, the inventors created a way to swap the mouse framework with human-like structures while keeping the specific mouse parts—the Complementarity Determining Regions (CDRs)—that actually grab onto disease targets. The key mechanism involves identifying specific amino acids in the mouse framework that support the shape of the CDRs and keeping those specific 'donor' amino acids in the final humanized version. This ensures the antibody remains effective at binding its target while appearing 'human' enough to avoid triggering an immune attack.

## What it does NOT cover

- Does not cover antibodies that are entirely human in origin (fully human antibodies).
- Does not cover antibodies that use only the donor CDRs without specific framework amino acids that support binding.
- Does not cover non-immunoglobulin proteins or other therapeutic molecules that are not antibodies.
- Does not cover the use of humanized antibodies for non-medical applications.

## The clever bit

The inventors realized that simply swapping the CDRs wasn't enough; they mathematically modeled the 3D structure to identify specific 'framework' amino acids that physically touch or support the CDRs, ensuring the antibody didn't lose its shape or binding strength during the humanization process.

## Real-world examples

1. Daclizumab (Zenapax) for preventing organ transplant rejection
2. Many early-generation monoclonal antibody cancer therapies
3. Treatments for rheumatoid arthritis and Crohn's disease

## Why it matters

This technology is the bedrock of modern monoclonal antibody therapy. Before this, mouse antibodies caused severe immune reactions in patients, making them unsuitable for long-term treatment. This patent enabled the development of blockbuster drugs that treat cancer, autoimmune diseases, and inflammatory conditions by making them safe for repeated human use.

## Frequently asked questions

### What does How Scientists Create Human-Friendly Antibodies for Medicine cover?

This patent describes a method for modifying mouse antibodies so human immune systems accept them as their own, allowing them to be used as powerful, long-lasting medical treatments.

### Who owns patent US 5585089?

Protein Design Labs Inc owns this patent, granted in 1996.

### When does this patent expire?

This patent has expired and is now in the public domain — anyone can use the invention freely.

### What is patent US 5585089 cited by?

This patent has been cited by 4274 later patents that build on its ideas.

### What problem does this patent solve?

This technology is the bedrock of modern monoclonal antibody therapy. Before this, mouse antibodies caused severe immune reactions in patients, making them unsuitable for long-term treatment. This patent enabled the development of blockbuster drugs that treat cancer, autoimmune diseases, and inflammatory conditions by making them safe for repeated human use.

### What does this patent NOT cover?

Does not cover antibodies that are entirely human in origin (fully human antibodies).

**Full plain-English explainer:** https://patentbrief.org/patent/us/5585089/remicade-infliximab

**Original patent:** https://patents.google.com/patent/US5585089

---

_Source: PatentBrief — https://patentbrief.org. Patent facts are from public records; the plain-English explanation is PatentBrief's._